Harmony Biosciences Holdings (HRMY)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Net income (ttm)	US$ in thousands	128,853	150,755	200,237	189,468	181,468	155,673	58,110	48,696	34,597	11,675	23,204
Revenue (ttm)	US$ in thousands	548,499	507,747	476,532	451,378	419,060	383,158	319,980	290,957	268,890	236,824	233,336
Net profit margin		23.49%	29.69%	42.02%	41.98%	43.30%	40.63%	18.16%	16.74%	12.87%	4.93%	9.94%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $128,853K ÷ $548,499K
= 23.49%

The net profit margin of Harmony Biosciences Holdings Inc has shown fluctuations over the past eight quarters. Q1 and Q2 of 2023 exhibited significant improvements with net profit margins of 40.17% and 40.14% respectively, indicating strong profitability during that period. However, the net profit margin decreased slightly in Q3 and Q4 of 2023 to 27.82% and 22.14% respectively.

Comparing the recent performance to the same quarters in the previous year, there has been a noticeable decline in profitability. Q4 of 2023, for example, had a net profit margin of 22.14% compared to 41.44% in Q4 of 2022. This downward trend suggests a potential challenge in maintaining or improving profitability levels.

Overall, while Harmony Biosciences Holdings Inc has demonstrated strong profitability in certain quarters, there is a need to closely monitor and potentially address the factors contributing to the recent declines in net profit margin to sustain long-term financial health.